Page 39 - MI-2-2

Microbes & Immunity Genetic therapy with HSV-1 vectors

for combination gene therapy applications. Gene Ther. 2002;76(17):8820-8833.
1998;5(11):1517-1530.
doi: 10.1128/jvi.76.17.8820-8833.2002
doi: 10.1038/sj.gt.3300755
59. Tanaka M, Nishiyama Y, Sata T, Kawaguchi Y. The role of
49. Mohr I, Gluzman Y. A herpesvirus genetic element which protein kinase activity expressed by the UL13 gene of herpes
affects translation in the absence of the viral GADD34 simplex virus 1: The activity is not essential for optimal
function. EMBO J. 1996;15(17):4759-4766. expression of UL41 and ICP0. Virology. 2005;341(2):301-312.
50. Daikoku T, Yamamoto N, Maeno K, Nishiyama Y. Role of doi: 10.1016/j.virol.2005.07.010
viral ribonucleotide reductase in the increase of dTTP pool 60. Todo T. Oncolytic virus therapy using genetically engineered
size in herpes simplex virus-infected Vero cells. J Gen Virol. herpes simplex viruses. Front Biosci. 2008;13:2060-2064.
1991;72(Pt 6):1441-1444.
doi: 10.2741/2823
doi: 10.1099/0022-1317-72-6-1441
61. Israyelyan A, Chouljenko VN, Baghian A, David AT,
51. Becker Y, Tavor E, Asher Y, Berkowitz C, Moyal M. Effect Kearney MT, Kousoulas KG. Herpes simplex virus type-
of herpes simplex virus type-1 UL41 gene on the stability 1(HSV-1) oncolytic and highly fusogenic mutants carrying
of mRNA from the cellular genes: Beta-actin, fibronectin, the NV1020 genomic deletion effectively inhibit primary
glucose transporter-1, and docking protein, and on virus and metastatic tumors in mice. Virol J. 2008;5:68.
intraperitoneal pathogenicity to newborn mice. Virus Genes.
1993;7(2):133-143. doi: 10.1186/1743-422X-5-68
doi: 10.1007/BF01702393 62. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial
of mutant herpes simplex virus G207 inoculated pre-
52. Broberg EK, Hukkanen V. Immune response to herpes and post-tumor resection for recurrent GBM. Mol Ther.
simplex virus and gamma134.5 deleted HSV vectors. Curr 2009;17(1):199-207.
Gene Ther. 2005;5(5):523-530.
doi: 10.1038/mt.2008.228.
doi: 10.2174/156652305774329267
63. Aghi MK, Chiocca EA. Phase ib trial of oncolytic herpes
53. Talloczy Z, Virgin HW 4 , Levine B. PKR-dependent virus G207 shows safety of multiple injections and
th
autophagic degradation of herpes simplex virus type 1. documents viral replication. Mol Ther. 2009;17(1):8-9.
Autophagy. 2006;2(1):24-29.
doi: 10.1038/mt.2008.275
doi: 10.4161/auto.2176
64. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic
54. Cheng G, Feng Z, He B. Herpes simplex virus 1 infection herpes simplex virus vector with enhanced MHC class I
activates the endoplasmic reticulum resident kinase presentation and tumor cell killing. Proc Natl Acad Sci U S
PERK and mediates eIF-2alpha dephosphorylation by the A. 2001;98(11):6396-6401.
gamma(1)34.5 protein. J Virol. 2005;79(3):1379-1388.
doi: 10.1073/pnas.101136398
doi: 10.1128/JVI.79.3.1379-1388.2005
65. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ
55. Epstein AL, Marconi P, Argnani R, Manservigi R. HSV-1- expression of soluble B7-1 in the context of oncolytic herpes
derived recombinant and amplicon vectors for gene transfer simplex virus induces potent antitumor immunity. Cancer
and gene therapy. Curr Gene Ther. 2005;5(5):445-458.
Res. 2001;61(1):153-161.
doi: 10.2174/156652305774329285
66. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination
56. Kaufman HL, Bines SD. OPTIM trial: A Phase III trial of an of oncolytic herpes simplex virus-1 vectors armed
oncolytic herpes virus encoding GM-CSF for unresectable with interleukin-12, interleukin-18, or soluble B7-1
stage III or IV melanoma. Future Oncol. 2010;6(6):941-949. results in enhanced antitumor efficacy. Clin Cancer Res.
2006;12(2):643-652.
doi: 10.2217/fon.10.66
doi: 10.1158/1078-0432.CCR-05-1494
57. Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II
study of oncolytic herpes simplex virus NV1020 in patients 67. Lee CY, Bu LX, Rennie PS, Jia WWG. An HSV-1 amplicon
with extensively pretreated refractory colorectal cancer system for prostate-specific expression of ICP4 to
metastatic to the liver. Hum Gene Ther. 2010;21(9):1119-1128. complement oncolytic viral replication for in vitro and in
vivo treatment of prostate cancer cells. Cancer Gene Ther.
doi: 10.1089/hum.2010.020
2007;14(7):652-660.
58. Kopp M, Klupp BG, Granzow H, Fuchs W, Mettenleiter TC.
Identification and characterization of the pseudorabies doi: 10.1038/sj.cgt.7701052
virus tegument proteins UL46 and UL47: Role for UL47 68. Kanai R, Tomita H, Hirose Y, et al. Augmented therapeutic
in virion morphogenesis in the cytoplasm. J Virol. efficacy of an oncolytic herpes simplex virus type 1 mutant

Volume 2 Issue 2 (2025) 31 doi: 10.36922/mi.7947